16 September 2026 editorial review · Item
Ladarixin (CXCR1/CXCR2 blockade): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: new record; substantive review 16 September 2026.
- Scope and findings: Added distinct negative-result entry. Checked the 2022 randomized publication and latest registry protocol, participant flow, primary analysis and adverse-event tables. Distinguished 289 run-in participants from 140 treatment-analysis participants, transformed C-peptide measure from natural units, and trial futility from a claim that every future ladarixin programme is discontinued.
- Primary sources checked: NCT04628481 — study record (registry); Ladarixin in new-onset type 1 diabetes: randomized placebo-controlled trial (peer-reviewed).
- Limits: The later results are sponsor-posted registry data, not a new peer-reviewed paper. Rare harms and alternative regimens are not established.